Several companies in the Asia Pacific region are involved in the manufacturing and distribution of diabetes pens, which are devices used for administering insulin. It's important to note that the landscape may have changed, and new companies may have emerged.
Novo Nordisk launched their new FlexTouch® insulin pen with an improved needle design for enhanced comfort and injection experience.Collaborated with healthcare providers and patient organizations to promote insulin pen usage and improve diabetes management in the region.
Eli Lilly and Company received regulatory approval for their Trulicity® pen in additional Asia Pacific markets, expanding access to this long-acting glucagon-like peptide-1 (GLP-1) agonist for blood sugar control.Partnered with digital health companies to develop connected pen systems for data tracking and personalized diabetes management.
Sanofi S.A. introduced their SoloStar® pen with pre-filled insulin cartridges for various insulin types, offering convenience and flexibility for patients.Focused on expanding their reach in emerging markets in the region to increase access to affordable and effective diabetes care.
BD (Becton, Dickinson and Company) developed new pen needle technologies with refined tips and coatings for reduced injection pain and improved user experience.Continued investing in manufacturing and distribution networks to ensure wider availability of their pen needles across the region.
Medtronic introduced their MiniMed™ 670G system with integrated insulin pen connectivity, allowing for automated insulin delivery based on continuous glucose monitoring data.Focused on developing next-generation closed-loop systems for personalized and optimal diabetes control.
List of Asia Pacific Diabetes Pen Key Companies in the Market
Asia Pacific Diabetes Pen Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)